Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Key Takeaway: Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, intended for the treatment of Cushing's syndrome. This resubmission follows previous interactions with the FDA. The company aims to address the needs of patients suffering from this condition with its investigational therapy.